Hypoxia Inducible Factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis
- 26 April 2011
- Vol. 66 (7), 909-918
- https://doi.org/10.1111/j.1398-9995.2011.02594.x
Abstract
To cite this article: Huerta‐Yepez S, Baay‐Guzman GJ, Bebenek IG, Hernandez‐Pando R, Vega MI, Chi L, Riedl M, Diaz‐Sanchez D, Kleerup E, Tashkin DP, Gonzalez FJ, Bonavida B, Zeidler M, Hankinson O. Hypoxia Inducible Factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy 2011; 66: 909–918. Abstract Background: New therapies are necessary to address inadequate asthma control in many patients. This study sets out to investigate whether hypoxia‐inducible factor (HIF) is essential for development of allergic airway inflammation (AAI) and therefore a potential novel target for asthma treatment. Methods: Mice conditionally knocked out for HIF‐1β were examined for their ability to mount an allergic inflammatory response in the lung after intratracheal exposure to ovalbumin. The effects of treating wild‐type mice with either ethyl‐3,4‐dihydroxybenzoate (EDHB) or 2‐methoxyestradiol (2ME), which upregulate and downregulate HIF, respectively, were determined. HIF‐1α levels were also measured in endobronchial biopsies and bronchial fluid of patients with asthma and nasal fluid of patients with rhinitis after challenge. Results: Deletion of HIF‐1β resulted in diminished AAI and diminished production of ovalbumin‐specific IgE and IgG1. EDHB enhanced the inflammatory response, which was muted upon simultaneous inhibition of vascular endothelial growth factor (VEGF). EDHB and 2ME antagonized each other with regard to their effects on airway inflammation and mucus production. The levels of HIF‐1α and VEGF increased in lung tissue and bronchial fluid of patients with asthma and in the nasal fluid of patients with rhinitis after challenge. Conclusions: Our results support the notion that HIF is directly involved in the development of AAI. Most importantly, we demonstrate for the first time that HIF‐1α is increased after challenge in patients with asthma and rhinitis. Therefore, we propose that HIF may be a potential therapeutic target for asthma and possibly for other inflammatory diseases.This publication has 37 references indexed in Scilit:
- Role of hypoxia-inducible factor 1α in modulating cobalt-induced lung inflammationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- Development of HIF‐1 inhibitors for cancer therapyJournal of Cellular and Molecular Medicine, 2009
- Enhanced Interferon-γ Gene Expression in T Cells and Reduced Ovalbumin-Dependent Lung Eosinophilia in Hypoxia-Inducible Factor-1-α-Deficient MiceInternational Archives of Allergy and Immunology, 2009
- Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compoundBlood, 2008
- A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-κB and hypoxia-inducible factor-1αExperimental & Molecular Medicine, 2007
- The N-Terminal Transactivation Domain Confers Target Gene Specificity of Hypoxia-inducible Factors HIF-1α and HIF-2αMolecular Biology of the Cell, 2007
- Target gene selectivity of hypoxia-inducible factor-α in renal cancer cells is conveyed by post-DNA-binding mechanismsBritish Journal of Cancer, 2007
- Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiolBiochemical and Biophysical Research Communications, 2004
- Conditional Disruption of the Aryl Hydrocarbon Receptor Nuclear Translocator (Arnt) Gene Leads to Loss of Target Gene Induction by the Aryl Hydrocarbon Receptor and Hypoxia-Inducible Factor 1Molecular Endocrinology, 2000